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Objectives: To investigate if a strategy combining clinical and ultrasound (US) 
assessment can select individuals with rheumatoid arthritis (RA) for sustained dose 
reduction of anti-tumor necrosis factor (TNF) therapies. 
Methods: As part of a real-world approach, patients with RA receiving anti-TNF 
therapies were reviewed in a dedicated biologics clinic. Patients not taking oral 
corticosteroids with both DAS28 remission (≤2.6) and absent synovitis on power 
doppler US (PDUS=0) for more than 6 months were invited to reduce their anti-TNF 
therapy dose by one third.  
Results: Between January 2012 and February 2014, a total of 70 patients underwent 
anti-TNF dose reduction. Combined DAS28 and PDUS remission was maintained by 
96% at 3 months, 63% at 6 months, 37% at 9 months and 34% at 18 months follow-
up. However, 88% of patients maintained at least low disease activity (LDA) with 
DAS28 <3.2 and PDUS ≤1 at 6 months. The addition of PDUS identified 8 patients 
(25% of those that flared), in DAS28 remission, with sub-clinically active disease. 
Those who maintained dose reduction were more likely to be rheumatoid factor (RF) 
negative (46% versus 17%; p=0.03) and have lower DAS-28 scores at biologic 
initiation (5.58 versus 5.96; p=0.038).  
Conclusions: Combined clinical and US assessment identifies individuals in remission 
who may be suitable for anti-TNF dose reduction and enhances safe monitoring for 
sub-clinical disease flares.  Despite long-standing severe RA, a sub-set of our cohort 
sustained prolonged DAS28 and PDUS remission.  Lower disease activity at biologic 
therapy initiation and RF status appeared predictive of sustained remission. 
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Significance and Innovations 
 
• First description of a real-world anti-TNF reduction strategy in patients with 
severe, chronic RA 
 
• It may be possible to use a strategy of combined clinical and ultrasound 
assessments to identify patients in remission suitable for anti-TNF dose 
reduction 
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In the treatment of rheumatoid arthritis (RA), biologic therapies including tumor 
necrosis factor inhibitors (anti-TNF) reduce disease activity
1-3
, preserve physical 
function and prevent joint damage and consequent disability
4-7
. Current guidelines 
for the management of RA propose rapid escalation of drug treatment to control 
disease activity 
8, 9
.  This approach encourages the early use of combination disease-
modifying anti-rheumatic drug (DMARD) therapy and the addition of biologic 
therapies for patients with poor prognostic signs or for those that fail to achieve 
prompt disease control with conventional DMARDs.  
 
Despite the clinical efficacy of anti-TNF therapies and a generally reassuring safety 
profile, some concerns remain regarding their long-term use due to the increased 
incidence of serious infections, tuberculosis
10,11
 and potential malignancies 
12
. The 
cost of anti-TNF therapy is also an important consideration and leads to restrictions 
on prescribing in many countries
13
. These combined factors have encouraged the 
investigation of the potential for anti-TNF dose reduction or discontinuation 




Evidence to date suggests that while anti-TNF therapy may be discontinued, at least 
in the short to medium term for some patients treated early in their disease 
course
17
, stopping anti-TNF in established disease leads to high rates of relapse
16
.  
For this reason it has been suggested that in established disease, dose reduction 
may be a more realistic approach and can be considered for patients in remission or 
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Means of accurately assessing disease activity are vital if anti-TNF therapy is going to 
be reduced. Clinical measures of remission alone, such as the DAS-28 assessment, 
may underestimate the degree of synovitis with the consequence that joint damage 
continues to accrue.  One way of addressing this concern is by using imaging 
technology such as ultrasound (US) or magnetic resonance imaging (MRI).  Previous 
studies have demonstrated that ongoing synovitis can be detected by US in up to 
62% of patients in clinical remission
19-21
 and that synovitis demonstrated by power 
doppler ultrasound (PDUS) correlates with both progression of structural damage
22
 
and risk of subsequent RA flare
23
.  As a result the use of US assessment for patients 




To explore this further we implemented a combined clinical and US assessment 
program as part of real-world care for patients receiving biologic therapies for RA.  
These combined assessments were then used to define individuals in both clinical 
and US remission as part of a strategy to select the most appropriate patients for 
dose reduction. 
 
Patients and Methods 
 
Ethical approval to report anonymised routine clinical data for the study was not 
required by the National Health Research Authority. However, our local Biologic 
Therapy Steering Group assessed progress and ensured the study was carried out to 
international standards of Good Clinical Practice (GCP).   
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As a pragmatic approach to achieving the best clinical outcomes we developed a 
dedicated clinic for patients with inflammatory arthritis receiving biologic therapy 
who were identified from within the existing departmental cohort and channeled 
into the new service. Hospital records were examined from diagnosis onwards and 
relevant characteristics entered into a biologics database. Patients all received 
standard care within the United Kingdom (UK) National Health Service (NHS). This 
provides comprehensive healthcare to all UK citizens free at the point of delivery 
and is funded from general taxation.  In the UK, to be eligible for anti-TNF therapy, 
patients must meet National Institute for Health and Care Excellence (NICE) criteria: 
DAS-28 score >5.1 on two occasions at least 1 month apart despite treatment with 




All patients attending the clinic underwent regular clinical examination (including 
DAS-28 assessment) by the same consultant or specialist nurse. In addition, patients 
underwent standardised PDUS imaging of their hands and wrists (Esoate Mylab 70, 
Esoate, Genova, Italy. Esaote Linear probe: LA435 (40mm, frequency setting 18 mHz 
for wrist, MCPJs and PIPJs); Mechanical Index: 0.65; PRF settings: Usual PRF set at 
750 Hz (possible range 125 Hz - 21.9 kHz)) by either a consultant rheumatologist or 
trained musculoskeletal ultrasonographer. A total of 18 joints were scanned, 
consisting of MCPJ 2-5, PIPJ 2-5 (dorsal midline longitudinal view) and wrists (3 
dorsal longitudinal views: midline (radio-lunate-capitate), medial (radio-carpal) and 
lateral (distal ulnar-carpal) bilaterally. PDUS findings were graded on a 0-3 semi-
quantitative scale where 0 indicated no vascularity and 3 indicated marked 
hyperaemia in line with previously proposed scales 
25,26
(images 1-3) Analysis of inter-
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operator variability (IOV) demonstrated substantial agreement (Kappa statistic = 
0.7545 SE 0.088 (95% CI=0.58-0.93) between ultrasonographers. 
 
From January 2012, all patients receiving a biologic therapy were routinely reviewed 
12 weeks after initiating therapy and then every 24 weeks in the biologics clinic. 
Dose reduction of anti-TNF was discussed with patients if they had been receiving 
anti-TNF therapy for more than a year, were not taking oral corticosteroids and were 
in DAS-28 remission (<2.6) for more than six months with no evidence of synovitis on 
PDUS. A one-third reduction was proposed (Adalimumab 40mg every 3 weeks; 
Etanercept 50mg every 10 days; Infliximab 2mg/kg per infusion; Certolizumab 
200mg every 3 weeks; Golimumab 50mg every 6 weeks) with follow up at 12 weeks 
and then every 24 weeks thereafter. Patients who did not meet these criteria, or 
elected not to undergo dose reduction, continued with routine 24-week follow-up 
(Figure 1). All patients were advised to telephone a dedicated specialist nurse help-
line if they felt their disease control deteriorated prior to the next planned 
consultation. All patients who telephoned the helpline were reviewed within 2 
working days. Following dose reduction, treatment failure was defined as either loss 
of DAS28 remission (DAS28 ≥2.6), evidence of synovitis on PDUS (score ≥1) in any 
joint or disease recurrence as defined by the patient. Patients who flared were re-
escalated to full treatment dose. 
 
Statistical Methods 
All continuous variables were checked for normality of the distributions. Differences 
in the baseline characteristics between patients undergoing dose reduction and 
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those continuing on standard dose anti-TNF were assessed for statistical significance 
using chi-squared test, Fisher’s exact tests, t-test or Mann-Whitney test or as 
appropriate, with a p≤0.05 considered as being statistically significant. In the 
patients who underwent anti-TNF dose reduction, univariate and multivariate 
regression analyses were performed to investigate factors influencing sustained 
remission. Multivariate analysis included adjustment for age, sex, ethnicity, 
rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA) status, 
duration of disease prior to anti-TNF therapy and duration of treatment with anti-
TNF prior to achieving remission. All analyses were performed with the statistical 
software SPSS ver.21 (IBM Corporation, USA). 
 
Results 
Between 1st January 2012 and 4th February 2014, 321 patients with RA (ACR-EULAR 
2010 criteria)
27
 were treated with a biologic, of whom 219 were receiving anti-TNF 
therapies. Patients had long-standing (mean 10.54 years), severe RA (mean DAS-28: 
5.75 on initiation of anti-TNF) and had generally failed multiple DMARDs prior to 
biologic initiation (mean 3.6 DMARDs) (Table 1).  
 
A total of 115 patients (36%) met eligibility criteria for anti-TNF dose reduction, of 
whom 70 patients agreed to undergo dose reduction. One patient was excluded 
from our analysis due to missing data. Older patients were more likely to agree to 
undertake anti-TNF reduction [mean (SD) age 61.86 (12.81) versus 57.74 (14.06) 
years, p=0.039].  
 
Page 9 of 28
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
10 
To understand what factors might predict sustained dose reduction we first 
performed a cross-sectional analysis of our cohort. This demonstrated that 37 
patients (54%) who underwent anti-TNF dose reduction had remained in sustained 
DAS28 and PDUS remission at an average of 10.2 months (SD 6.52) follow-up. 32 
patients (46%) had flared with this occurring typically between months 3 and 9 
(mean time to flare 7.65 months; SD 5.17).  
 
Sustained remission was more likely in patients with a lower DAS-28 at anti-TNF 
initiation [5.58 (SD 0.72) versus 5.96 (SD 0.85), p=0.04] and also in patients who 
were RF negative [44.1% versus 16.7%, p=0.03] (Table 2). There were no other 
significant differences in measured baseline characteristics between the two groups 
and no differences in the component parts of the DAS28 score (tender joint count; 
swollen joint count; VAS score or ESR).Using logistic regression modeling, lower DAS-
28 at anti-TNF initiation was associated with a significantly greater probability of 
sustained dose reduction [OR = 2.04; 95%CI 1.006 to 4.133, p=0.048]. No other 
statistically significant associations were identified.  
 
To further analyze how and when patients flared we then examined individual case 
data. This demonstrated that following dose reduction 96% maintained combined 
DAS28 (<2.6) and PDUS remission (PDUS=0) at 3 months, 63% at 6 months, 37% at 9 
months and 34% after 18 months follow-up. However, 88% of patients maintained 
at least low disease activity (LDA) with DAS28 <3.2 and PDUS ≤1 at 6 months. In 
patients who maintained remission beyond 9 months, this appeared to be largely 
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sustained with only 2 further drop-outs due to disease flare by 18 months follow up 
(Figure 2).  
 
Of the patients who failed to maintain remission on a reduced dose of anti-TNF, 41% 
demonstrated an increase in DAS28 score only, 25% demonstrated development of 
synovitis using PDUS only and 25% demonstrated both an increased DAS28 and 
PDUS activity. Mean change in DAS28 was +1.14 (SD 1.02) for those patients 
demonstrating increased clinical disease activity.  Using an increase in DAS28 of >1.2 
to define a flare of RA, only 34% of patients in our cohort would have been classified 
as flaring following dose reduction though half of these patients also demonstrated 
PDUS at the time of re-escalation.  Three patients (9%) felt as if they had flared 
following dose reduction despite maintaining DAS28 and PDUS defined measures of 
remission.  
 
Following disease flare and treatment re-escalation 6 patients (19%) returned to 
combined DAS28 and PDUS remission, 6 (19%) patients were in DAS28 remission 
(with active synovitis on PDUS assessment) and 15 patients (47%) demonstrated LDA 
(DAS ≥2.6 to <3.2). Five patients (15%) had moderate disease activity (DAS28 ≥3.2 to 
<5.1) despite re-escalation of treatment after an average 15 months further follow-
up. No patients had severe disease activity (DAS28 ≥ 5.1) or required a change of 
biologic treatment following anti-TNF dose reduction. 
 
Discussion 
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Using clinical and US criteria to define remission in a group of patients with severe 
longstanding RA we have shown that at 6 months following dose reduction 63% 
remained in a stringent remission criteria of DAS28<2.6 and PDUS=0. It is also worth 
pointing out that 88% of patients maintained at least low disease activity (LDA) with 
DAS28 <3.2 and PDUS ≤1 at 6 months. However, longer-term follow-up suggests that 
by 18 months around two thirds of patients had flared. Interestingly, flares appeared 
to occur predominantly between months 3 and 9 after dose reduction.  Further flare 
was rare after this time point suggesting that patients declare their “flare 
phenotype” early. In addition, certain characteristics such as being RF negative and 
having a lower DAS28 at anti-TNF initiation seemed to reduce the likelihood of flare, 
though the difference in mean DAS28 between the two groups was small (0.38) and 
less than measurement error for DAS28 (0.6)
 28
.Our results suggest that it may be 
possible to identify individuals who are most appropriate for dose reduction using a 
combination of biomarkers (including PDUS assessment) and clinical scoring 
systems. 
 
This study has several advantages. It is the first to report the outcomes of anti-TNF 
dose reduction as part of real-world clinical practice. While other studies have 
demonstrated the value of US assessment when making decisions about escalating 
treatment
29, 30
 this study is unique in including the US assessment of synovitis as part 
of the clinical decision-making algorithm when tapering biologic therapy. Because of 
the uncertainties that still exist when integrating US into clinical decision making, 
and because our patients had severe longstanding disease, we adopted a cautious 
approach defining US remission as PDUS =0 in all joints, even though the significance 
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of grade 1 change is uncertain and can occur in patients with osteoarthritis 
31
 and a 
proportion of healthy volunteers 
32
. We elected to make treatment decisions on the 
basis of PDUS only and ignored grayscale changes because their significance in later 
RA remains uncertain
33
. Following anti-TNF dose reduction 8 patients were identified 
as having sub-clinical synovitis despite DAS28 remission using US at routine follow-
up appointments.  In 4 of these patients PDUS was only grade I (in at least two 
joints), and in the remaining 4 PDUS was >1 (in at least two joints). 
 
We ensured that patients were involved in a shared decision-making process when 
considering their dose reduction. We chose a dose reduction of one third primarily 
because of concerns regarding disease flare following reduction in a cohort of 
patients with such long-standing severe disease. In addition, this was a real-world 
clinical situation, and our policy of shared-care decision-making meant that we felt 
patients were unlikely to agree to a voluntary 50% reduction outside of a more 
formal clinical trial. Even with this cautious approach it is interesting to note that of 
patients who appeared clinically eligible for anti-TNF reduction a significant 
proportion (40%) elected not to take part. This group were younger [55.75 years (SD 
16.04) versus 61.86 years (SD 12.81), p=0.01) but were otherwise well matched with 
those that underwent dose reduction. The age differential may reflect younger 
patients concerns regarding the loss of remission state and its impact on quality of 
life and work participation.  
 
Other recent studies have explored the possibility of dose reduction.  Compared to 
our results, the PRESERVE (Prospective, Randomized Etanercept Study to Evaluate 
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Reduced dose Etanercept combined with MTX versus full dose Etanercept combined 
with MTX versus MTX alone) trial 
16
, reported that 60.2% of patients maintained 
DAS28 remission (<2.6) following a 50% reduction in the dose of etanercept at 9 
months follow-up. However, our population had significantly longer disease duration 
(mean 10.5 years versus 6.3 years) and higher disease activity (mean baseline DAS 
5.75 versus 4.4) compared to the PRESERVE participants.  
 
Our data suggests that lower DAS28 at biologic initiation and being RF negative may 
be predictive of the likely success of anti-TNF dose reduction. The results of ongoing 
trials such as PRIZE (Productivity and Remission in a Randomized Controlled Trial of 
etanercept versus Standard of Care in Early Rheumatoid Arthritis) 
34
 and DOSERA 
(Discontinuing Etanercept in Subjects With Rheumatoid Arthritis) 
35
 should provide 
further clarity regarding the suitability of dose reduction for patients with either very 
early, or very late RA respectively.  
 
There is uncertainty regarding the long-term prospects for maintaining remission on 
reduced dose biologics. Our results suggest that in long-standing RA, the majority of 
patients will experience disease flare, though it is reassuring that 85% of those who 
flare will re-attain LDA or remission following return to standard dose anti-TNF 
therapy. Real-world studies such as this can provide important long-term follow up 
data to inform future decision-making. While dose reduction may be possible within 
the context of time-limited clinical trials, the practicality of translating such clinical 
trial data to everyday practice over the longer term remains to be established. 
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There are a number of limitations to our study. Firstly, US is well recognized as being 
subject to user variability. We used either a single trained consultant rheumatologist 
or a single trained MSK ultrasonographer who both perform scans routinely in 
theclinic with good IOV.. While our US room is temperature controlled, we did not 
control for other factors that may influence the detection of synovitis by PDUS, such 
as concomitant NSAIDs use, joint position, alcohol or caffeine consumption or recent 
physical exertion 
36
. For pragmatic reasons we did not use a validated US scoring 
system such as the 12- joint
37
 or 7-joint count
38 
nor did we assess foot synovitis
39
. 
Therefore we may have under-estimated the overall likelihood of disease remission 
though we would have expected patients with active arthritis in non-assessed joints 
to decline dose reduction. Finally, because the criteria that we applied to define 
successful dose reduction are stricter than current EULAR targets of LDA or 
remission
9
 this introduces the possibility that we over-identified disease flare. 
Consequently, our data may well underestimate the true value of dose reduction. 
 
Conclusions    
Anti-TNF dose reduction by one third is possible for some patients with severe long-
standing RA and can be undertaken safely within the confines of routine clinical 
practice. The use of semi-quantitative PDUS scoring in addition to clinical 
assessment and disease characteristics may enable clinicians to identify and safely 
monitor individuals in whom this can be considered. 
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Figure 1 - Schematic for Patient Pathway  
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Figure 2 – Percentage of individuals maintaining sustained DAS28 and PDUS remission following dose 
reduction by time  
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Examples of Grade I to III Power Doppler Ultrasound (PDUS) signal  
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 Table 1 - Anti-TNF population characteristics* 
 Characteristic Non-reducers Dose Reducers P value 
Subjects, N 149 69  
Female Sex, N (%) 162 (74.0) 52 (74.3) 0.942 
Age, years  57.74 ± 14.06 61.86 ± 12.81 0.039 
Caucasian (%) 139 (93.3) 65 (92.9) 0.906 
Current Smoker (%) 24 (18.5) 7 (10.1) 0.305 
RhF positive, (%) 97(70.3) 45 (69.2) 0.878 
ACPA positive, (%) 57 (71.3) 24 (68.6) 0.772 
Disease duration until first biologic (months)  125.5 ±  100.7 129.5 ± 119.0 0.092 
 DMARDs prior to biologic, N 3.60 ±2.05 3.57 ±1.85 0.212 
DAS28 Score prior to biologic initiation  5.66 ±0.99 5.75 ±0.83 0.287 
DMARD co-prescribed with anti-TNF (%) 122 (81.88) 59 (84.29) 0.069 
* Values are mean ± SD unless otherwise indicated. RhF = rheumatoid factor; ACPA = anti-citrullinated 
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 Table 2 - Characteristics of sustained and non-sustained anti-TNF reducers * 
 
 Characteristic Sustained Non-Sustained P Value 
Subjects, N 37 32  
Female Sex, N (%) 24 (64.9) 27 (84.4) 0.066 
Age, (years)  60.57 ± 12.37 64.5 ± 11.72 0.065 
Caucasian (%) 35 (94.6) 29 (90.6) 0.526 
Current Smoker (%) 4 (10.8) 3 (9.7) 0.988 
RhF positive, (%) 19 (55.9) 25 (83.3) 0.030 
ACPA positive, (%) 12 (60) 12 (80.0) 0.281 
Disease duration until first biologic, (months)  123.1 ± 111.7 141.7 ± 123.1 0.313 
 DMARDs prior to biologic, N 3.64 ± 1.79 3.39  ± 1.66 0.693 
DAS28 Score prior to biologic initiation  5.58 ± 0.72  5.96 ±  0.85 0.040 
DMARD co-prescribed with anti-TNF (%) 33 (89.2) 25 (78.1) 0.452 
* Values are mean ± SD unless otherwise indicated. RhF = rheumatoid factor; ACPA = anti-citrullinated 
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